MedTrace Logo

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

NCT03724097 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-09-14

No results posted yet for this study

Summary

This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes at the level of gene expression and intracellular signaling pathways. By applying the database of known molecular targets of anticancer target drugs it allows to rank potential efficacies of target drugs.

Conditions

Interventions

OTHER

RNA sequencing

Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.

OTHER

Transcriptome analysis

Analysis of RNA-seq data using the Oncobox algorithm.

DRUG

target drug with the score above 0,1

target drug with the score above 0,1

DRUG

target drug with the score equal or below 0,1

target drug with the score equal or below 0,1

DRUG

non-target drug

non-target drug

DRUG

palliative care

palliative care

Sponsors & Collaborators

  • Oncobox Ltd

    collaborator UNKNOWN

  • Vitamed LLC

    collaborator UNKNOWN

  • N.N. Blokhin National Medical Research Center of Oncology

    collaborator OTHER

  • Kaluga Regional Clinical Oncology Center

    collaborator OTHER

  • Multidisciplinary medical holding SM-Clinic

    collaborator UNKNOWN

  • Oncological Clinical Dispensary No. 1 of the Moscow City Health Department

    collaborator UNKNOWN

  • OmicsWay Corp.

    lead INDUSTRY

Principal Investigators

  • Anton A Buzdin, Ph.D., D.Sc · OmicsWay Corp.

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-17
Primary Completion
2021-04-01
Completion
2022-11-01
FDA Drug
Yes

Countries

  • United States
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724097 on ClinicalTrials.gov